Medline ® Abstract for Reference 191
of 'Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects'
Nasal septal perforation from bevacizumab: a discussion of outcomes, management, and pharmacovigilance.
Ramiscal JA, Jatoi A
Curr Oncol Rep. 2012;14(4):307.
To date, the published literature describes 18 reports of nasal septal perforation in cancer patients with the administration of bevacizumab. This complication was detected during post-marketing surveillance of bevacizumab. How should patients who develop this complication be managed? This discussion summarizes suggestions for management of bevacizumab-associated nasal septal perforation and, as relevant to healthcare providers, discusses some of the practical aspects of post-marketing pharmacovigilance.
Mayo Clinic Medical School, Rochester, MN, USA.